Key result
Next-generation sequencing and emerging gene therapies offer promising personalized treatments for DCM.
Why the study?
Despite advances in next-generation sequencing, challenges remain in interpreting genetic variants, correlating them with phenotypic expression, and understanding epigenetic modifications in dilated cardiomyopathy.
This review highlights the complex genetic basis of dilated cardiomyopathy, emphasizing the role of genes like TTN and LMNA, and the potential for precision medicine approaches.
No takes yet. Share an insight, caveat, or question.
May inform genetic testing in DCM patients; leaves open prospective validation of gene therapies.
Vitanova et al. (2026) conducted a review in Dilated cardiomyopathy. Dilated cardiomyopathy is a heterogeneous genetic disorder where advances in next-generation sequencing and emerging gene therapies offer promising personalized treatment approaches.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: